MANTLE CELL LYMPHOMA (MCL)
Clinical trials for MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: oral drug targets resistant cancer
Disease control OngoingThis study tests an experimental oral drug called rocbrutinib in 62 adults with mantle cell lymphoma whose cancer has come back or stopped responding to a previous targeted therapy. The goal is to see if the drug can shrink tumors. Participants take the drug by mouth, and the stu…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New hope for lymphoma patients: drug combo shows promise in early trial
Disease control OngoingThis early-phase study tests a new drug (acalabrutinib) combined with standard treatments (bendamustine and rituximab, or venetoclax and rituximab) in 72 adults with untreated mantle cell lymphoma. The main goal is to check safety and side effects. Participants must not have had …
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE1 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
New hope for tough lymphoma: targeted drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests a drug called ACP-196 (acalabrutinib) in 124 adults with mantle cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients' tumors shrink or disappear. Participants take the drug by mouth, and researchers monitor …
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New combo aims for deep remission in lymphoma patients
Disease control OngoingThis study tests a combination of three drugs (acalabrutinib, venetoclax, and rituximab) in people with untreated mantle cell lymphoma. The goal is to see if the treatment can make the cancer undetectable in the blood and keep it under control. Participants who respond well may s…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 14, 2026 12:05 UTC